Damanhour University
damanhour.edu.egTotal trials
75
Active
4
Phase 3
1
Total enrollment
9,216
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| ETT cuff pressure monitoring, ETT suctioning, cough augmentation technique, swallowing exercises,: Nebulized budesonide 1mg and IV methylprednisolone 40 mg we | — | — | — | — | — | 1 | |
| Dapagliflozin | — | — | — | — | — | 1 |
Next readouts
- 2025-03-01
- 2025-03-08
Top conditions
- Breast Cancer6
- Heart Failure5
- Healthy Normotensive Participants3
- Healthy3
- Coronary Artery Disease3
- Sepsis2
- Breast Cancer Patients2
- Chemotherapeutic Toxicity2
Frequently asked questions about Damanhour University
- How many clinical trials does Damanhour University have on ClinicalTrials.gov?
- Damanhour University is listed as the lead sponsor on 75 clinical trials in ClinicalTrials.gov, 4 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Damanhour University's trials are in Phase 3?
- 1 of Damanhour University's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Damanhour University focus on?
- Damanhour University's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Heart Failure, Healthy Normotensive Participants, Healthy, Coronary Artery Disease.
- When are Damanhour University's next clinical trial readouts?
- Damanhour University has 2 upcoming primary-completion readouts tracked here; the soonest is “Anemia-Related Outcomes in Patients With CKD Treated With Dapagliflozin”, expected around 2025-03-01.